A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
Pharmacokinetics of O6-benzylguanine in Pediatric Patients with Central Nervous System Tumors: A Pediatric Oncology Group Study
2004
Clinical Cancer Research
Purpose: To report the results of the first pharmacokinetic study in pediatric patients of O 6 -benzylguanine (O 6 BG), which irreversibly inactivates the DNA repair protein alkylguanine-alkyltransferase, thus enhancing the cytotoxicity of nitrosoureas. Experimental Design: As part of a Pediatric Oncology Group Phase I study, 120 mg/m 2 of O 6 BG was administered i.v. over 1 h, before 1,3-bis(2-chloroethyl)-1-nitrosourea administration in children with recurrent or refractory brain tumors.
doi:10.1158/1078-0432.ccr-03-0123
pmid:15297409
fatcat:hgbxkok7brdenh4m6efyasaace